| Literature DB >> 28396884 |
Jens Reimann1, Diana Lehmann1, Steven A Hardy1, Gavin Falkous1, Charlotte V Y Knowles1, Rachel L Jones1, Wolfram S Kunz1, Robert W Taylor1, Cornelia Kornblum1.
Abstract
Entities:
Year: 2017 PMID: 28396884 PMCID: PMC5384303 DOI: 10.1212/NXG.0000000000000147
Source DB: PubMed Journal: Neurol Genet ISSN: 2376-7839
FigureClinical, histopathologic, and molecular genetic characterization of the m.1660G>A MT-TV mutation
(A) Camptocormia as the main clinical feature of the patient harboring the novel 1660G>A MT-TV mutation. (B) Serial hematoxylin and eosin (B.a), modified Gomori trichrome staining (B.b), succinate dehydrogenase (SDH) (B.c), and cytochrome c oxidase (COX)-SDH histochemistry (B.d) showing ragged red fibers and COX-deficient fibers (scale bar = 50 μm). (C) Result of the quadruple OXPHOS immunofluorescence analysis, confirming the presence of fibers lacking both complex I (NDUFB8) and complex IV (COX-1) expressions. (D) Single muscle fiber mutation load segregation. The graph shows the mutation load measured in individual COX-positive (closed dots) and COX-deficient fibers (open dots) laser microdissected from the patient muscle biopsy. (E) Schematic representation of the cloverleaf structure of the mitochondrial (mt)-tRNA Val molecule and the corresponding location of the pathogenic mutation (marked in red) and previous reported mt-tRNA Val mutations (black). (F) Phylogenetic conservation of the appropriate regions of the mt-tRNA Val gene sequence for the m.1660G>A mutation.